TY - JOUR
T1 - Cerebral microvascular complications of type 2 diabetes
T2 - stroke, cognitive dysfunction, and depression
AU - van Sloten, Thomas T.
AU - Sedaghat, Sanaz
AU - Carnethon, Mercedes R.
AU - Launer, Lenore J.
AU - Stehouwer, Coen D.A.
N1 - Funding Information:
TTvS is supported by a VENI research grant (916.19.074) from the Netherlands Organization for Scientific Research and the Netherlands Organization for Health Research and Development, a Dutch Heart Foundation research grant ( 2018T025 ), and a travel grant from L'institut Servier. LJL is supported by the Intramural Research Program (National Institute on Aging, US National Institutes of Health).
Funding Information:
TTvS is supported by a VENI research grant (916.19.074) from the Netherlands Organization for Scientific Research and the Netherlands Organization for Health Research and Development, a Dutch Heart Foundation research grant (2018T025), and a travel grant from L'institut Servier. LJL is supported by the Intramural Research Program (National Institute on Aging, US National Institutes of Health).
Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/4
Y1 - 2020/4
N2 - Adults with type 2 diabetes are at an increased risk of developing certain brain or mental disorders, including stroke, dementia, and depression. Although these disorders are not usually considered classic microvascular complications of diabetes, evidence is growing that microvascular dysfunction is one of the key underlying mechanisms. Microvascular dysfunction is a widespread phenomenon in people with diabetes, including effects on the brain. Cerebral microvascular dysfunction is also apparent in adults with prediabetes, suggesting that cerebral microvascular disease processes start before the onset of diabetes. The microvasculature is involved in the regulation of many cerebral processes that when impaired predispose to lacunar and haemorrhagic stroke, cognitive dysfunction, and depression. Main drivers of diabetes-related cerebral microvascular dysfunction are hyperglycaemia, obesity and insulin resistance, and hypertension. Increasing amounts of data from observational studies suggest that diabetes-related microvascular dysfunction is associated with a higher risk of stroke, cognitive dysfunction, and depression. Cerebral outcomes in diabetes might be improved following treatments targeting the pathways through which diabetes damages the microcirculation. These treatments might include drugs that reduce dicarbonyl compounds, augment cerebral insulin signalling, or improve blood–brain barrier permeability and cerebral vasoreactivity.
AB - Adults with type 2 diabetes are at an increased risk of developing certain brain or mental disorders, including stroke, dementia, and depression. Although these disorders are not usually considered classic microvascular complications of diabetes, evidence is growing that microvascular dysfunction is one of the key underlying mechanisms. Microvascular dysfunction is a widespread phenomenon in people with diabetes, including effects on the brain. Cerebral microvascular dysfunction is also apparent in adults with prediabetes, suggesting that cerebral microvascular disease processes start before the onset of diabetes. The microvasculature is involved in the regulation of many cerebral processes that when impaired predispose to lacunar and haemorrhagic stroke, cognitive dysfunction, and depression. Main drivers of diabetes-related cerebral microvascular dysfunction are hyperglycaemia, obesity and insulin resistance, and hypertension. Increasing amounts of data from observational studies suggest that diabetes-related microvascular dysfunction is associated with a higher risk of stroke, cognitive dysfunction, and depression. Cerebral outcomes in diabetes might be improved following treatments targeting the pathways through which diabetes damages the microcirculation. These treatments might include drugs that reduce dicarbonyl compounds, augment cerebral insulin signalling, or improve blood–brain barrier permeability and cerebral vasoreactivity.
UR - http://www.scopus.com/inward/record.url?scp=85081689446&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081689446&partnerID=8YFLogxK
U2 - 10.1016/S2213-8587(19)30405-X
DO - 10.1016/S2213-8587(19)30405-X
M3 - Review article
C2 - 32135131
AN - SCOPUS:85081689446
SN - 2213-8587
VL - 8
SP - 325
EP - 336
JO - The Lancet Diabetes and Endocrinology
JF - The Lancet Diabetes and Endocrinology
IS - 4
ER -